Optimi Health Secures $100M Credit Line for Psychedelic Drug Production

Optimi Health Corp. secured a US$100 million equity line of credit from Seven Knots, LLC. The company specializes in manufacturing regulated psychedelic drug products.

This agreement grants Optimi the right to sell common shares to Seven Knots throughout the facility's term. The arrangement provides a flexible method for the company to raise capital as needed.

Optimi may draw funds in increments of up to US$2 million. These shares will be sold at a 3% discount to the prevailing market price.

The deal remains contingent on a registration statement becoming effective with the U.S. Securities and Exchange Commission. Optimi issued a US$1.5 million convertible promissory note to Seven Knots to secure the commitment.